Eli Lilly Downgraded To Neutral From Buy At Goldman Sachs By: TalkMarkets January 16, 2018 at 05:46 AM EST Goldman Sachs analyst Jami Rubin downgraded Eli Lilly to Neutral and cut her price target for the shares to $95 from $98. Read More >> Related Stocks: Eli Lilly Novo Nordisk A/S ADR